Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARA | Q07869 | 5/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21679279 | 0.93 | HCRTR2 (0.37) | HCRTR2PPARGPPARANTRK1PPARD | |
| SCHEMBL21679257 | 0.87 | SMN1; SMN2 (0.36) | MEN1KMT2APPARGPPARASMN1; SMN2 | |
| SCHEMBL21678960 | 0.83 | HCRTR2 (0.39) | HCRTR2PPARGPPARANTRK1PPARD | |
| SCHEMBL21679392 | 0.81 | MEN1 (0.36) | MEN1KMT2AHCRTR2SMN1; SMN2ALDH1A1 | |
| SCHEMBL21679323 | 0.78 | CCNE1 (0.39) | MEN1KMT2ASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL21679115 | 0.78 | PPARG (0.40) | PPARGPPARASMN1; SMN2PPARDALDH1A1 | |
| SCHEMBL21679359 | 0.76 | HCRTR2 (0.41) | HCRTR2PPARGPPARASMN1; SMN2PPARD | |
| SCHEMBL21679366 | 0.75 | CCNE1 (0.38) | MEN1KMT2ANTRK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL15637053 | 0.72 | KDM4E (0.49) | HCRTR2PPARGPPARANTRK1SMN1; SMN2 | |
| SCHEMBL21679079 | 0.71 | SMYD3 (0.40) | MEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | JANSSEN SCIENCES IRELAND UNLIMITED CO (US) | 2022-11-03 | — | — | US | disclosed |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | Janssen Sciences Ireland Unlimited Company (IE) | 2021-07-06 | — | — | US | disclosed |
| EP-3814326-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-05 | — | — | EP | disclosed |
| CN-112513017-A | Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced diseases | 爱尔兰詹森科学公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-02-13 | — | — | US | disclosed |
| US-20160367548-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS INC (US) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348571-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MEN1 3958/4885KMT2A 3463/4885HCRTR2 3804/4885 |
| US-11053235-B2 | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases | DPYD, TYMP, HAVCR2 | MEN1 3612/4885KMT2A 2626/4885HCRTR2 4107/4885 |
| US-20200048242-A1 | DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | DPYD, HAVCR2, TYMP | MEN1 3958/4885KMT2A 3463/4885HCRTR2 3804/4885 |
| US-20160367548-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | MEN1 3295/4885KMT2A 468/4885HCRTR2 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.